Theravance Biopharma (TBPH) 7th Annual Evercore ISI HealthCONx Conference summary

Company overview and financial position

• Holds a strong financial position with a marketed product and a late-stage pipeline asset.

• YUPELRI, a nebulized LAMA for COPD, is marketed in partnership and generates significant cash flow.

• Economic rights to Trelegy provide future milestone and royalty income.

• Ampreloxetine, targeting MSA with NOH, is in phase 3 development.

• Financial strength allows self-funding of R&D with minimal cash burn.

YUPELRI market performance and growth

• YUPELRI is the only nebulized long-acting muscarinic antagonist for COPD, serving a stable 10% patient segment.

• Achieved $62.2 million in quarterly net sales, nearing a $250 million annual run rate.

• Delivers $40 million annual cash profit, with 35% of incremental sales flowing to profit.

• Growth driven by hospital formulary wins, therapeutic interchange, and patient preference for nebulization.

• Long IP runway to 2039 supports future expansion.

Hospital and community strategy

• Focus on hospital formulary access and automatic therapeutic interchange in high-target hospitals.

• Economic and clinical benefits drive adoption, including reduced therapy waste and improved patient outcomes.

• Coordinated discharge planning ensures continuity of care and reduces readmissions.

• Community growth opportunity by adding YUPELRI to existing LABA therapy.